Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.

NCT00850252 is registered in ClinicalTrials.gov with Cytograft Tissue Engineering as lead sponsor.

NCT NCT00850252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00850252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.
Lead sponsor
Cytograft Tissue Engineering
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2004
Completion date
December 31, 2012
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esrd, hemodialysis